Skip to content
Medical Health Aged Care, Science

Finding answers for sudden cardiac death in young people

Centenary Institute 2 mins read

Each week in Australia, up to three young people die suddenly and unexpectedly from sudden cardiac death, often due to an undiagnosed genetic heart condition. These conditions typically go unnoticed until tragedy strikes, leaving families devastated and searching for answers.

 

The Centenary Institute is launching its inaugural Giving Day, to raise vital funds for research into the genetic causes of sudden cardiac death, particularly in young people, and to provide much-needed answers to grieving families.

 

Taking place on Wednesday 9th April, 2025, the Giving Day will be a key moment for donors, to support the Institute’s research into genetic heart disease, paving the way for targeted life-saving treatments for young people. Funds raised will also aid genetic testing and counselling services, helping families understand why their loved one died and to assess potential risks for relatives.

 

Associate Professor Richard Bagnall, Head of the Centenary Institute’s Centre for Cardiovascular Research emphasised the urgent need for increased funding in this critical health area.

 

“Sudden cardiac death can strike without warning, even in seemingly healthy young people,” said Associate Professor Bagnall. “Our research is dedicated to identifying the genetic causes of these conditions, improving diagnosis, enhancing risk assessment and ultimately saving lives.”

 

Associate Professor Bagnall highlighted that families seeking genetic testing and counselling at the Genetic Heart Disease Clinic could face an overwhelming 12-month wait, leaving many without information and support.

 

“Additional funding from the Giving Day will help reduce these wait times, ensuring that more families receive the answers and support they need, when they need it most,” he said.

 

Dedicated advocates for Centenary’s Centre for Cardiovascular Research are the Bellingham family, who lost their 24-year-old son, Aaiden, to sudden cardiac death. Since then, they have dedicated themselves to raising awareness and funds.

 

“Losing Aaiden was devastating. No family should have to experience this pain," said Adrian Bellingham. “The work being done at Centenary is essential, not only in understanding why these deaths happen but in preventing them. The Giving Day is an opportunity for all of us to contribute to research and clinical care that can save lives.”

 

Centenary Institute’s Giving Day takes place on Wednesday 9th April, 2025. Donations can be made before this date. Every contribution will fund vital research and family care.

 

To donate or learn more, visit www.donate.centenary.org.au/

 

[ENDS]

 


Key Facts:

Available for Interview:

Associate Professor Richard Bagnall, Head of the Centre for Cardiovascular Research, Centenary Institute.

Adrian and Meg Bellingham, Parents of Aaiden Bellingham who suffered from sudden cardiac death at age 24.


About us:

About the Centenary Institute

The Centenary Institute is a world-leading independent medical research institute, closely affiliated to the University of Sydney and the Royal Prince Alfred Hospital. Our research spans the critical areas of cancer, cardiovascular disease, rare diseases, inflammation, infectious diseases, healthy ageing and biomedical AI. Our strength lies in uncovering disease mechanisms and applying this knowledge to improve diagnostics and treatments for patients.

For more information about the Centenary Institute, visit centenary.org.au


Contact details:

For all media and interview enquiries, please contact

Tony Crawshaw, Media and Communications Manager, Centenary Institute on 0402 770 403 or email: [email protected]

Media

More from this category

  • Medical Health Aged Care
  • 17/12/2025
  • 13:11
GE HealthCare

GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners

300+ advanced CT scanners to be installed in public hospitals across 38 provinces by 2028, to support early diagnosis and treatment of non-communicable diseases.…

  • Contains:
  • Science
  • 17/12/2025
  • 12:27
WEHI

New antimalarial drug candidate shows potential for fighting resistance and reducing malaria transmission

Researchers have developed a new antimalarial drug candidate designed to address the growing challenge of drug resistance and potentially reduce malaria transmission. The first-in-class…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 17/12/2025
  • 12:03
Jane Morgan Management

LTR Pharma surpasses 1,000 SPONTANĀ® prescriptions under TGA Special Access Scheme

Highlights More than 1,000 SPONTAN® prescriptions issued under the TGA Special Access Scheme Growing prescriber network with continued uptake in complex ED cases, including post-prostate cancer patients Real-world insights informing US commercial strategy ahead of ROXUS® launch in H1 CY2026 LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that more than 1,000 SPONTAN® prescriptions have now been issued in Australia under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS Category B). SPONTAN is being prescribed for patients with unmet clinical needs, including men who have not achieved adequate benefit from traditional oral PDE5 inhibitor…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.